These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32134431)

  • 1. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
    Golmard L; Golmard JL; Stoppa-Lyonnet D
    JAMA Oncol; 2020 Apr; 6(4):588-589. PubMed ID: 32134431
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes.
    Rousseau B; Vidal J; Diaz LA
    JAMA Oncol; 2020 Apr; 6(4):589-590. PubMed ID: 32134429
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply.
    Wang F; Zhao Q; Xu RH
    JAMA Oncol; 2020 Apr; 6(4):590. PubMed ID: 32134432
    [No Abstract]   [Full Text] [Related]  

  • 4. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.
    Chen YX; Wang ZX; Yuan SQ; Jiang TJ; Huang YS; Xu RH; Wang F; Zhao Q
    Clin Transl Med; 2021 Sep; 11(9):e524. PubMed ID: 34586735
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
    Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
    Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency.
    Bourdais R; Rousseau B; Pujals A; Boussion H; Joly C; Guillemin A; Baumgaertner I; Neuzillet C; Tournigand C
    Crit Rev Oncol Hematol; 2017 May; 113():242-248. PubMed ID: 28427513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POLD1 and POLE Gene Mutations in Jewish Cohorts of Early-Onset Colorectal Cancer and of Multiple Colorectal Adenomas.
    Rosner G; Gluck N; Carmi S; Bercovich D; Fliss-Issakov N; Ben-Yehoyada M; Aharon-Caspi S; Kellerman E; Strul H; Shibolet O; Kariv R
    Dis Colon Rectum; 2018 Sep; 61(9):1073-1079. PubMed ID: 30086056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
    Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis.
    Valle L; Hernández-Illán E; Bellido F; Aiza G; Castillejo A; Castillejo MI; Navarro M; Seguí N; Vargas G; Guarinos C; Juarez M; Sanjuán X; Iglesias S; Alenda C; Egoavil C; Segura Á; Juan MJ; Rodriguez-Soler M; Brunet J; González S; Jover R; Lázaro C; Capellá G; Pineda M; Soto JL; Blanco I
    Hum Mol Genet; 2014 Jul; 23(13):3506-12. PubMed ID: 24501277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
    Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
    Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
    Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
    Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.
    Jansen AM; van Wezel T; van den Akker BE; Ventayol Garcia M; Ruano D; Tops CM; Wagner A; Letteboer TG; Gómez-García EB; Devilee P; Wijnen JT; Hes FJ; Morreau H
    Eur J Hum Genet; 2016 Jul; 24(7):1089-92. PubMed ID: 26648449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
    Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
    Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivating Mutations in Exonuclease and Polymerase Domains in DNA Polymerase Delta Alter Sensitivities to Inhibitors of dNTP Synthesis.
    Zhang J; Hou D; Annis J; Sargolzaeiaval F; Appelbaum J; Takahashi E; Martin GM; Herr A; Oshima J
    DNA Cell Biol; 2020 Jan; 39(1):50-56. PubMed ID: 31750734
    [No Abstract]   [Full Text] [Related]  

  • 17. Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer.
    Wisdom AJ; Kirsch DG
    Cancer Res; 2020 Dec; 80(24):5459-5461. PubMed ID: 33323408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.
    Zhang J; Zhou N; Lin A; Luo P; Chen X; Deng H; Kang S; Guo L; Zhu W; Zhang J
    Cancer Immunol Immunother; 2021 Jan; 70(1):137-151. PubMed ID: 32653938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of exogenous MSH6 and POLD1 expression on the mutation rate of the HPRT locus in a human colon cancer cell line with mutator phenotype, DLD-1.
    Yabuta T; Shinmura K; Yamane A; Yamaguchi S; Takenoshita S; Yokota J
    Int J Oncol; 2004 Mar; 24(3):697-702. PubMed ID: 14767555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
    Qu J; Jiang M; Wang L; Zhao D; Qin K; Wang Y; Tao J; Zhang X
    Biomed Pharmacother; 2020 Jul; 127():109996. PubMed ID: 32388240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.